Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
EA Pharma Co., Ltd.
Takeda Pharmaceutical Company
Eisai Co., Ltd.
- License Information
-
More Information
Article History
Received: 25 August 2023
Accepted: 5 November 2023
First Online: 10 January 2024
Declarations
:
: JH is a medical doctor at the National Hospital Osaka Minami Medical Center and received a consultant fee from EA Pharma Co., Ltd, a marketing authorization holder of Actonel® tablets. YA and SK are current employees of EA Pharma Co., Ltd., and TI is a current employee of Eisai Co., Ltd. that markets Actonel® tablets. The authors have no other conflicts of interest to declare.
